Multi-Centre, Prospective, Observational Study of Patient Reported Outcomes in Patients Diagnosed With Chronic Migraine and Treated With OnabotulinumtoxinA for Injection (BOTOX®) (PREDICT)
Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 10 Sep 2017
At a glance
- Drugs Botulinum-Toxin-A (Primary)
- Indications Migraine
- Focus Therapeutic Use
- Acronyms PREDICT
- Sponsors Allergan
- 10 Sep 2017 Baseline results from a prospective, observational trial (PREDICT) presented at the 2017 International Headache Society
- 06 Sep 2017 According to an Allergan media release, data from the study will be presented at the upcoming 18th Congress of the International Headache Society (IHC2017).
- 25 Jul 2017 Planned primary completion date changed from 1 Dec 2016 to 30 Dec 2018.